stockhead15h
Small cap gems set to blow the lights out in 2025 (part two)
After a stellar 2024 for recovering small to mid caps sector, our experts scour the sector for more overlooked nuggets.
stockhead1d
Criterion’s small cap gems poised to star in 2025 (part one)
There are no dead-certs in small-cap investing, but here are some plays that just might rise and shine in 2025.
stockhead1d
Criterion: What to do when your shares are taken into custody
Investors should ask questions about custodial-based share arrangements by which they do not have legal ownership ...
stockhead1d
Closing Bell: ASX closes week higher as Appen, Novonix race ahead
ASX rallies on commodity boost with BrainChip and DroneShield leading the charge, but 2025 volatility looms with key risks on ...
stockhead2d
Gold Digger: The gold M&A deals on the experts’ chess boards
With two juniors entering trading halts, more gold M&A could be coming in 2024. With prices near record highs, 2025 looks ...
stockhead2d
How new, smarter TVs are transforming the Boxing Day Test viewer experience
AI is beginning to influence yet more aspects of regular life, changing how Aussies with the right tech see the Boxing Day ...
stockhead2d
Resources Top 5: Japan’s Sumitomo wades deeper into critical minerals mission
The owner of a fluorspar deposit in northern WA says Japan's Sumitomo could take a 22.5% stake in a $60m JV to develop the ...
stockhead2d
ASX Lunch Wrap: Local market’s good form continues as Brainchip and Droneshield soar
ASX rallies on commodity boost as Brainchip and Droneshield soar, while Aussies may have splashed $1.3B on Boxing Day sales.
stockhead2d
Top stock pickers reveal end-of-year tips
It’s been a rocky December for investors but these stock-tipping experts still see opportunities and growth in the market.
stockhead2d
2024 IPO Performers: Which fresh listings stole the stage this year?
Resources managed to steal the show, with two stocks gaining +190%. The winner was Sun Silver (ASX:SS1) with a 212% gain on its listing price of $0.20, even hitting highs of $1.12 in October. It’s ...
stockhead2d
Biocurious: Behind Race Oncology’s quest to prevent chemo from being worse than the disease
Cancer survival has dramatically increased, but chemotherapy can lead to lasting organ damage Race plans to launch a cardioprotective study of a repurposed cancer drug, bisantrene Following an ...